Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: I. Potent and Selective Histamine H3 Receptor Antagonist with Drug-Like Properties

Histamine H3 receptor antagonists are being developed to treat a variety of neurological and cognitive disorders that may be ameliorated by enhancement of central neurotransmitter release. Here, we present the in vitro pharmacological and in vivo pharmacokinetic profiles for the nonimidazole, benzofuran ligand ABT-239 [4-(2-{2-[(2R)-2-methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile] and compare it with several previously described imidazole and nonimidazole H3 receptor antagonists. ABT-239 binds to recombinant human and rat H3 receptors with high affinity, with pKi values of 9.4 and 8.9, respectively, and is over 1000-fold selective versus human H1, H2, and H4 histamine receptors. ABT-239 is a potent H3 receptor antagonist at recombinant human and rat receptors, reversing agonist-induced changes in cAMP formation (pKb = 7.9 and 7.6, respectively), guanosine 5′-O-(3-[35S]thio) triphosphate ([35S]GTPγS) binding (pKb = 9.0 and 8.3, respectively), and calcium mobilization (human pKb = 7.9). ABT-239 also competitively reversed histamine-mediated inhibition of [3H]histamine release from rat brain cortical synaptosomes (pKb = 7.7) and agonist-induced inhibition of contractile responses in electric field stimulated guinea pig ileal segments (pA2 = 8.7). Additionally, ABT-239 is a potent inverse agonist, inhibiting constitutive [35S]GTPγS binding at both rat and human H3 receptors with respective pEC50 values of 8.9 and 8.2. ABT-239 demonstrates good pharmacokinetic characteristics in rat, dog, and monkey with t1/2 values ranging from 4 to 29 h, corresponding with clearance values and metabolic turnover in liver microsomes from these species, and good oral bioavailability ranging from 52 to 89%. Thus, ABT-239 is a selective, nonimidazole H3 receptor antagonist/inverse agonist with similar high potency in both human and rat and favorable drug-like properties.

[1]  S. L. Yates,et al.  High antagonist potency of GT-2227 and GT-2331, new histamine H3 receptor antagonists, in two functional models. , 1998, European journal of pharmacology.

[2]  Genomic organization and characterization of splice variants of the human histamine H3 receptor. , 2001 .

[3]  Michael Williams,et al.  Two Novel and Selective Nonimidazole Histamine H3 Receptor Antagonists A-304121 and A-317920: I. In Vitro Pharmacological Effects , 2003, Journal of Pharmacology and Experimental Therapeutics.

[4]  T. Lovenberg,et al.  Constitutive activity of histamine h(3) receptors stably expressed in SK-N-MC cells: display of agonism and inverse agonism by H(3) antagonists. , 2001, The Journal of pharmacology and experimental therapeutics.

[5]  J. Schwartz,et al.  Auto-inhibition of brain histamine release mediated by a novel class (H3) of histamine receptor , 1983, Nature.

[6]  B. McMillen Comparative chronic effects of buspirone or neuroleptics on rat brain dopaminergic neurotransmission , 2005, Journal of Neural Transmission.

[7]  A. Hancock,et al.  Species-related pharmacological heterogeneity of histamine H(3) receptors. , 2001, European journal of pharmacology.

[8]  R. Leurs,et al.  Therapeutic potential of histamine H3 receptor agonists and antagonists. , 1998, Trends in pharmacological sciences.

[9]  M. Giovannini,et al.  H3 receptor modulation of the release of neurotransmitters in vivo , 1998 .

[10]  M. Williams,et al.  Pharmacological and behavioral properties of A-349821, a selective and potent human histamine H3 receptor antagonist. , 2004, Biochemical pharmacology.

[11]  J. Schwartz,et al.  Therapeutic implications of constitutive activity of receptors: the example of the histamine H3 receptor. , 2003, Journal of neural transmission. Supplementum.

[12]  M. Jackson,et al.  Cloning and functional expression of the human histamine H3 receptor. , 1999, Molecular pharmacology.

[13]  W. Chai,et al.  Non-imidazole heterocyclic histamine H3 receptor antagonists. , 2003, Bioorganic & medicinal chemistry letters.

[14]  A. Hancock,et al.  Molecular modeling and pharmacological analysis of species-related histamine H3 receptor heterogeneity , 2003, Neuropharmacology.

[15]  A. Hancock,et al.  Medicinal chemistry and biological properties of non-imidazole histamine H3 antagonists. , 2004, Mini reviews in medicinal chemistry.

[16]  A. Hancock,et al.  Genetic and pharmacological aspects of histamine H3 receptor heterogeneity. , 2003, Life sciences.

[17]  H. Schild pA, A NEW SCALE FOR THE MEASUREMENT OF DRUG ANTAGONISM , 1997, British journal of pharmacology and chemotherapy.

[18]  C. Dvorak,et al.  A new class of diamine-based human histamine H3 receptor antagonists: 4-(aminoalkoxy)benzylamines. , 2003, Journal of medicinal chemistry.

[19]  S. M. Knudsen,et al.  1-alkyl-4-acylpiperazines as a new class of imidazole-free histamine H(3) receptor antagonists. , 2004, Journal of medicinal chemistry.

[20]  B. Conklin,et al.  Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors. , 1999, Analytical biochemistry.

[21]  R. Obach,et al.  Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes. , 1999, Drug metabolism and disposition: the biological fate of chemicals.

[22]  Holger Stark,et al.  High constitutive activity of native H3 receptors regulates histamine neurons in brain , 2000, Nature.

[23]  M. Williams,et al.  Two Novel and Selective Nonimidazole H3 Receptor Antagonists A-304121 and A-317920: II. In Vivo Behavioral and Neurophysiological Characterization , 2003, Journal of Pharmacology and Experimental Therapeutics.

[24]  J. Boutin,et al.  Genomic organization and characterization of splice variants of the human histamine H 3 receptor , 2022 .

[25]  Min Zhang,et al.  Pharmacological Properties of ABT-239 [4-(2-{2-[(2R)-2-Methylpyrrolidinyl]ethyl}-benzofuran-5-yl)benzonitrile]: II. Neurophysiological Characterization and Broad Preclinical Efficacy in Cognition and Schizophrenia of a Potent and Selective Histamine H3 Receptor Antagonist , 2005, Journal of Pharmacology and Experimental Therapeutics.

[26]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[27]  R. Leurs,et al.  [3H]‐thioperamide as a radioligand for the histamine H3 receptor in rat cerebral cortex , 1996, British journal of pharmacology.

[28]  R. Leurs,et al.  Identification of rat H3 receptor isoforms with different brain expression and signaling properties. , 2001, Molecular pharmacology.

[29]  J. Black,et al.  Characterization of the binding of [3H]‐clobenpropit to histamine H3‐receptors in guinea‐pig cerebral cortex membranes , 1999, British journal of pharmacology.

[30]  M. Jackson,et al.  Cloning and functional expression of the human histamine H3 receptor. , 1999, Molecular pharmacology.

[31]  M. Decker,et al.  Effects of histamine H3 receptor ligands GT-2331 and ciproxifan in a repeated acquisition avoidance response in the spontaneously hypertensive rat pup , 2002, Behavioural Brain Research.

[32]  P. Leff,et al.  Further concerns over Cheng-Prusoff analysis. , 1993, Trends in pharmacological sciences.

[33]  G. Coruzzi,et al.  The Histamine H3 Receptor , 2000 .

[34]  A. Hancock,et al.  A new class of potent non-imidazole H(3) antagonists: 2-aminoethylbenzofurans. , 2004, Bioorganic & medicinal chemistry letters.

[35]  A. Hancock,et al.  Characterization of Histaminergic Receptors , 2000 .

[36]  J. Witkin,et al.  Selective histamine H3 receptor antagonists for treatment of cognitive deficiencies and other disorders of the central nervous system. , 2004, Pharmacology & therapeutics.

[37]  M. Erlander,et al.  Cloning of rat histamine H(3) receptor reveals distinct species pharmacological profiles. , 2000, The Journal of pharmacology and experimental therapeutics.

[38]  C R Ganellin,et al.  Distinct pharmacology of rat and human histamine H3 receptors: role of two amino acids in the third transmembrane domain , 2000, British journal of pharmacology.

[39]  J. Schwartz,et al.  Neurochemical and behavioral effects of ciproxifan, a potent histamine H3-receptor antagonist. , 1998, The Journal of pharmacology and experimental therapeutics.

[40]  S. Hastrup,et al.  Characteristics of recombinantly expressed rat and human histamine H3 receptors. , 2002, European journal of pharmacology.

[41]  J. Barnes,et al.  Pharmacological activity of VUF 9153, an isothiourea histamine H3 receptor antagonist. , 1993, European journal of pharmacology.

[42]  J. Schwartz,et al.  Highly potent and selective ligands for histamine H3-receptors , 1987, Nature.